How to score accreditation for a radiotherapy theranostics program
Wes Folds, nuclear/PET clinical specialist, Intersocietal Accreditation Commission (IAC), discusses a new radiotherapy theranostics accreditation program at the Radiology Business Management Association (RBMA) 2025 annual meeting in Nashville, Tennessee.
Folds says there has been an explosion of interest in theranostics, mainly driven by the U.S. Food and Drug Administration (FDA) clearance of the radiopharmaceuticals Pluvicto (lutetium Lu-177 vipivotide tetraxetan), used to treat metastatic castration-resistant prostate cancer, and Lutathera (lutetium Lu-177 dotatate), to treat advanced neuroendocrine tumors.
IAC partnered with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) on the radiopharmaceutical therapy accreditation program and announced the first facilities to earn this designation in January.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.